Mirati and MD Anderson team up on KRAS; Sanofi inks deal with a Harvard spinout for oral biologics
Mirati, the other KRAS-focused biotech, is getting some extra ammo as it looks to leapfrog Amgen in the hunt for the first, most effective and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
